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OBJECTIVE— Metformin is associated with reduced cancer-related morbidity and mortal-
ity. The aim of this study was to assess the effect of metformin on cancer incidence in a consec-
utive series of insulin-treated patients.
RESEARCH DESIGN ANDMETHODS— A nested case-control study was performed
in a cohort of 1,340 patients by sampling, for each case subject, age-, sex-, and BMI-matched
control subjects from the same cohort.
RESULTS— During a median follow-up of 75.9 months, 112 case patients who developed
incident cancer and were compared with 370 control subjects. A significantly lower proportion
of case subjects were exposed to metformin and sulfonylureas. After adjustment for comorbidity,
glargine, and total insulin doses, exposure to metformin, but not to sulfonylureas, was associated
with reduced incidence of cancer (odds ratio 0.46 [95% CI 0.25–0.85], P  0.014 and 0.75
[0.39–1.45], P  0.40, respectively).
CONCLUSIONS— The reduction of cancer risk could be a further relevant reason for
maintaining use of metformin in insulin-treated patients.
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S everal studies have shown that met-formin is associated with reducedcancer-related morbidity and mor-
tality (1–4), due to improvement in insu-
lin sensitivity (5) or to the activation of
AMP-activated protein kinase (6). In in-
sulin-treated patients, the reduction in in-
sulin doses determined by metformin (7)
could theoretically produce a decrease in
cancer incidence.
RESEARCH DESIGN AND
METHODS— We analyzed oral hy-
poglycemic treatments in patients in-
cluded in a case-control study nested
within a cohort of insulin-treated type 2
diabetic patients, which had been de-
signed for the assessment of the effect on
cancer incidence of different insulin ana-
logs (8). In brief, 1,340 consecutive type 2
diabetic outpatients (746 women and 594
men, aged [mean  SD] 63.1  14.9
years) with no history or previous hospi-
talizations for malignancies, who were liv-
ing in Florence, Italy, were referred to the
University Diabetes Clinics, and started
insulin therapy in 1998–2007, were en-
rolled in the study. Demographic and
clinical information was obtained from
clinical records, including anthropomet-
ric measures, A1C (measured every 3–4
months with high-performance liquid
chromatography [Menarini Diagnostics,
Florence, Italy]; upper normal limit
5.9%), and serum creatinine, part of rou-
tine follow-up. Comorbidity was assessed
with the Charlson comorbidity score
(CCS), which includes diabetes and its
complications and other diseases (9).
Patients with incident cancer up to 31
December 2008 were identified at first
hospital admission (from the Regional
Hospital Discharge system) or death
(from the Mortality Registry of Tuscany)
with ICD-9 codes 140 –209. A nested
case-control study dataset was generated
from the cohort study dataset by sampling
control subjects from the risk sets. For
each case subject, the control subjects (up
to five) were chosen randomly from those
members of the cohort at risk for the same
follow-up time as the case subject. Age,
sex, and BMI classes at insulin initiation
were considered as additional categorical
variables for matching, using Stata 9.0
and the procedure “sttocc.” Exposure to
hypoglycemic drugs was assessed from
enrollment to incident cancer in case sub-
jects and during the corresponding time
from initiation of insulin therapy in
matched control subjects, retrieving pre-
scriptions from clinical records. If the last
available visit had occurred 3 months
before the event (or matching date), a
telephone contact was attempted to col-
lect further information on subsequent
drug use; if the contact was unsuccessful,
the patient was assumed to have contin-
ued the last reported therapy.
The exposure of case subjects and con-
trol subjects to different drugs (proportion
of patients exposed, time of exposure, and
mean daily dose [MDD], units per kilogram
per day) for each compound) was com-
pared using 2 and Mann-Whitney tests
whenever appropriate. Multivariate analy-
ses were performed with conditional logis-
tic regression, which takes into account the
matching structure, using total insulin and
glargine MDD and CCS as covariates. All
analyses were carried out with SPSS 15.0
and Stata 9.0.
RESULTS— The 112 patients with in-
cident cancer (gastrointestinal, 29; lung,
16; pancreatic, 14; and other, 53) during
a median follow-up of 75.9 (range 27.4–
133.7) months (case subjects) were com-
pared with 370 control subjects. A
significantly lower proportion of case
subjects were exposed to metformin and
sulfonylureas during follow-up. Among
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those exposed, the length of exposure to
sulfonylureas was greater in case subjects
than in control subjects, whereas no such
difference was observed for metformin.
MDD for metformin and glyburide did
not differ between case subjects and con-
trol subjects (Table 1).
In a multivariate model, with adjust-
ment for CCS, glargine MDD, and total
MDD of insulin, exposure to metformin
was associated with reduced incidence of
cancer (OR 0.46 [95% CI 0.25–0.85],
P 0.014; 0.37 [0.15–0.92], P 0.032,
and 0.55 [0.23–1.32], P  0.18, in men
and women, respectively), whereas sulfo-
nylurea treatment was not (0.75 [0.39–
1.45], P  0.40). When cancer occurred
within 12 months of follow-up of enroll-
ment and matching control subjects were
excluded, the ORs for cancer were 0.53
[0.26–1.06], P  0.074 and 0.86 [0.42–
1.79], P 0.69, for any exposure to met-
formin and sulfonylureas, respectively;
the corresponding figures for exposure
12 months during follow-up were 0.30
[0.14–0.66], P 0.003 and 0.70 [0.34–
1.41], P  0.31, for metformin and sul-
fonylureas, respectively.
CONCLUSIONS— The present re-
sults confirm previous findings on the
protective effect of metformin with re-
spect to malignancies (1–3). Interest-
ingly, this effect was evident even after
adjustment for insulin doses, suggesting
that the protective action of metformin
cannot be entirely attributed to its insu-
lin-sparing effects. Although insulin has
mitogenic properties (10) and metformin
reduces insulin requirements in type 2 di-
abetic patients (7), the decrease in insulin
doses determined by metformin does not
explain the observed reduction of cancer
incidence. This result supports the notion
of other mechanisms, independent of in-
sulin dose (6,11,12). It is possible that
patients not receiving metformin have a
greater incidence of cancer due to comor-
bidities; the adjustment for a comorbidity
score does not eliminate completely the
possibility of a prescription bias. Con-
versely, the protective effect of sulfonyl-
ureas did not retain significance in
multivariate analysis, suggesting that the
higher proportion of sulfonylurea-treated
patients among control subjects could be
either due to lower comorbidity or met-
formin cotreatment. The possibility of
misdiagnosis of diabetes type in some
case subjects should be considered.
Current recommendations suggest a
trial of metformin, unless contraindi-
cated, in all insulin-treated type 2 diabetic
patients (13). This recommendation is
motivated by the beneficial effects of met-
formin on insulin sensitivity, insulin
doses, and glucose control. Beyond all
those effects, the reduction of cancer risk
could be a further relevant reason for
maintaining use of metformin in insulin-
treated patients.
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